MoonLake Immunotherapeutics (MLTX) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.64
↓-29% vs avg
5yr avg: 5.14
30Y Low1.5·High7.5
ROE
↑
-60.0%
↓+21% vs avg
5yr avg: -75.7%
30Y Low-175%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MLTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MoonLake Immunotherapeutics currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $850M | $3.4B | $3.0B | $308M | $365M | $168M |
| Enterprise Value | $969M | $591M | $3.2B | $2.5B | $269M | $372M | $167M |
| P/E Ratio → | -4.87 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 3.64 | 2.79 | 7.51 | 5.78 | 4.48 | — | 1.50 |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MLTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
MLTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -60.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -60.0% | -60.0% | -24.6% | -12.4% | -175.0% | -106.4% | -0.1% |
| ROA | -50.4% | -50.4% | -23.7% | -11.9% | -115.5% | -84.9% | -0.1% |
| ROIC | -114.2% | -114.2% | -62.8% | -85.0% | -392.6% | -75.4% | — |
| ROCE | -58.7% | -58.7% | -29.4% | -18.5% | -225.2% | -102.0% | -0.1% |
MLTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $335M exceeds total debt of $76M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.01 | 0.01 | 0.00 | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.85 | -0.39 | -0.87 | -0.57 | — | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -33.78 | -33.78 | — | — | — | — | — |
Net cash position: cash ($335M) exceeds total debt ($76M)
MLTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
MoonLake Immunotherapeutics's current ratio of 9.27x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 51.59x to 9.27x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 9.27 | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 | 12.93 |
| Quick Ratio | 9.27 | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 | 12.93 |
| Cash Ratio | 8.66 | 8.66 | 19.94 | 51.28 | 9.41 | 0.38 | 10.67 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
MLTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MoonLake Immunotherapeutics does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $64M | $63M | $49M | $29M | $37M | $15M |
Peer Comparison
Compare MLTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MLTXYou | $1B | -4.9 | — | — | — | — | -60.0% | -114.2% | — |
 UCB | $4B | 12.8 | 8.8 | 9.9 | 66.0% | 27.5% | 9.3% | 8.2% | 0.4 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 NVO | $203B | 12.6 | 9.3 | 44.6 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See MLTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLTX vs UCB
Side-by-side business, growth, and profitability comparison vs United Community Banks, Inc..
Start ComparisonMLTX — Frequently Asked Questions
Quick answers to the most common questions about buying MLTX stock.
What is MoonLake Immunotherapeutics's P/E ratio?
MoonLake Immunotherapeutics's current P/E ratio is -4.9x. This places it at the 50th percentile of its historical range.
What is MoonLake Immunotherapeutics's ROE?
MoonLake Immunotherapeutics's return on equity (ROE) is -60.0%. The historical average is -63.1%.
Is MLTX stock overvalued?
Based on historical data, MoonLake Immunotherapeutics is trading at a P/E of -4.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.